Highlights a biologically plausible but underexplored pathway (polySia/ST8SIA2/sialidase) that could yield biomarkers or enzyme-targeted strategies to modulate neuroinflammation in Parkinson’s, though it is a broad review with limited direct, actionable therapeutic data.

Findings highlight a real-world functional visual deficit in PD that could serve as a noninvasive outcome measure or symptom-target for interventions, but the paper offers limited mechanistic or therapeutic-discovery insight.

Provides useful negative evidence that this specific PINK1 variant is unlikely to be a PD risk biomarker or direct therapeutic target, helping researchers avoid pursuing a low-yield locus and focus on other PINK1 sites, mitochondrial mechanisms, or multi-locus/gene–environment interactions.

Provides useful context for differentiating FTLD-related parkinsonian syndromes (eg, PSP, corticobasal syndrome) from Parkinson's disease and may inform patient selection and diagnostic stratification in neurodegeneration research, but offers limited direct mechanistic or therapeutic leads for…

Nasal airflow metrics may provide a noninvasive biomarker for axial/speech motor deterioration and for monitoring interventions, but the work offers limited direct mechanistic or therapeutic targets for PD drug discovery.

This is clinically informative for adaptive functional neurosurgery and symptom control strategies but provides minimal mechanistic or therapeutic-discovery insights for drug development, highlighting need for larger studies to assess efficacy and safety.

While not providing therapeutic mechanisms, the validated, mechanism-informed pain phenotyping tool supports standardized assessment in clinical studies and could help stratify patients for future mechanism-targeted pain interventions in PD.

Provides evidence that pause metrics are a non-invasive behavioral biomarker of cognitive-linguistic and motor-speech impairment in PD useful for monitoring progression or intervention effects, but offers limited direct insight for molecular therapeutic discovery.

Highlights metal-induced DNA structural damage as a potential modifier of neurodegeneration (including PD), but provides limited direct therapeutic targets or translational strategies for Parkinson's drug discovery.

Although it offers no molecular or biomarker insights, the study provides actionable guidance for designing and implementing rehabilitation interventions and trial protocols that could enhance adherence, functional outcomes, and real-world translational uptake in Parkinson's therapeutics.

This paper supports nonpharmacologic auditory cueing (music or fractal metronome) as clinically useful rehabilitation strategies and highlights stride-time DFA as a sensitive outcome measure for gait interventions, but it offers limited direct insights for molecular or drug-target discovery.

The work supports group singing as a low-risk psychosocial adjunct that can improve wellbeing and stress-related biomarkers in Parkinson's patients, but it provides little mechanistic or directly drug-discovery–actionable insight.

Provides a rigorous theoretical framework for how toxic proteins can propagate and fluctuate in the brain—insight that can inform conceptual models of proteinopathies relevant to Parkinson's—but it offers little direct, actionable guidance for therapeutic targets, biomarkers, or translational…

This study has limited direct value for therapeutic discovery but is useful for trial design and patient-centered care because psychosocial interventions that reduce loneliness/demoralization may improve adherence, retention, and subjective outcomes in PD research.

While it offers little molecular or mechanistic insight for drug discovery, the work identifies clinically relevant heterogeneity in embodied empathy that could inform patient stratification, outcome measures, and targeted non-pharmacological or behavioral interventions in PD research.

Has limited direct therapeutic discovery value—it's primarily a diagnostic/classification tool that could aid patient stratification or trial recruitment if rigorously validated, but it offers no mechanistic insights or intervention targets for Parkinson's disease.

While not providing mechanistic or therapeutic leads, the study identifies caregiver burden and communication factors that can influence patient adherence, quality-of-life endpoints, and clinical trial retention, informing supportive interventions that complement drug development.

Suggests actionable translational avenues—microbiome-targeted therapies and repurposing diabetes drugs (e.g., GLP-1 agonists)—that could influence PD progression, but the lack of an abstract and primary data limits immediate therapeutic impact and prioritization.

Identifies a mechanistic, targetable axis connecting exosome-delivered miRNA, microglial metabolic/inflammatory state and neuroprotection, supporting development of exosome- or LDHA/miR-1278-focused therapeutic strategies for Parkinson's disease.

This work is valuable for informing equity, mentorship, and workforce policies that can indirectly influence research capacity, but it offers negligible direct insight or actionable targets for Parkinson's therapeutic discovery (no biological mechanisms, biomarkers, or interventions reported).